Fundraising FoxAtea Pharmaceuticals
NASDAQ: AVIRUnicorn · $1.6BBoston, US · Founded 2012 · Massachusetts corporation · 3 known investors
Find your way into Atea Pharmaceuticals
Sign up to see every warm intro you have to Atea Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atea Pharmaceuticals team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV). Its work spans antiviral drug discovery, medicinal chemistry, biology, and virology.
Founders & leadership
Atea Pharmaceuticals was founded in 2012 by Jean-Pierre Sommadossi, Ph.D. and Jean-Pierre Sommadossi.
JS
Jean-Pierre Sommadossi, Ph.D.Co-founder
AC
Andrea CorcoranChief Financial Officer, Executive Vice President, Legal, and Secretary
WF
Wayne FosterExecutive Vice President and Chief Accounting Officer
Board
BL
Bruno LucidiBoard director
EZ
Evgeny ZatsevBoard director
FY
Frank YuBoard director
GC
Gerald ChanBoard director
BP
Bruce PolskyBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$175.9M disclosed across 4 rounds · 2013–2020
▶$107.5MraisedMay 2020 · 37 investors · BiotechnologyRule 506(b)
▶$107.5MraisedMay 2020 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
- Andrew Hack, M.D., Ph.D.Director
- Bruno LucidiDirector
- Bruce PolskyDirector
- Andrea CorcoranExecutive Officer
- Bihua ChenDirector
- Franklin BergerDirector
- Grigory BorisenkoDirector
- Isaac Cheng, M.D.Director
- Offering amount
- $215M
- Amount sold
- $107.5M
- Sales commissions
- $500K
- Placement agents
- William Blair
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27.6MraisedJul 2018 · 38 investors · BiotechnologyRule 506(b)
▶$27.6MraisedJul 2018 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gerald ChanDirector
- Evgeny ZatsevDirector
- Jean-Pierre SommadossiExecutive Officer, Director
- Bruce PolskyDirector
- Fan YuDirector
- Andrea CorcoranExecutive Officer
- Bihua ChenDirector
- Bruno LucidiDirector
- Offering amount
- $27.6M
- Amount sold
- $27.6M
- Sales commissions
- $119.5K
- Placement agents
- CIM Securities, LLC
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.8MraisedSep 2016 · 29 investors · BiotechnologyRule 506(b)
▶$20.8MraisedSep 2016 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bruno LucidiDirector
- Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
- Evgeny ZatsevDirector
- Frank YuDirector
- Gerald ChanDirector
- Bruce PolskyDirector
- Offering amount
- $20.8M
- Amount sold
- $20.8M
- Sales commissions
- $167K
- Placement agents
- CIM Securities
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$20MraisedSep 2014 · 59 investors · OtherRule 506(b)
▶$20MraisedSep 2014 · 59 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jean-Pierre Sommadossi, Ph.D.Executive Officer, Director
- Offering amount
- $20M
- Amount sold
- $20M
- Minimum investment
- $25K
- Sales commissions
- $811.1K
- Placement agents
- Brookline Group, LLC
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$1.6Bvaluation at IPOOct 2020 · $24.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 2
PrescriberPointPrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place. It serves healthcare providers in the medication access and prescribing space.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Atea Pharmaceuticals.
Frequently asked questions
- What does Atea Pharmaceuticals do?
- Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV). Its work spans antiviral drug discovery, medicinal chemistry, biology, and virology.
- Who founded Atea Pharmaceuticals?
- Atea Pharmaceuticals was founded by Jean-Pierre Sommadossi, Ph.D., Jean-Pierre Sommadossi in 2012.
- Who are Atea Pharmaceuticals's investors?
- Atea Pharmaceuticals's investors include ATEM Capital Fund, Bain Capital Life Sciences, RA Capital.
- How much funding has Atea Pharmaceuticals raised?
- Atea Pharmaceuticals has disclosed $175.9M raised across 4 rounds.
- Where is Atea Pharmaceuticals headquartered?
- Atea Pharmaceuticals is headquartered in Boston, US.